Animal models of depressive illness: The importance of chronic drug treatment

Current Pharmaceutical Design

Volumn 11, Issue 2, 2005, Pages 171-203

  Mitchell, P J ^a   Redfern, P H ^a  

^a University of Bath   (United Kingdom)

Author keywords

Agonistic behaviour; Animal models of depression; Antidepressant treatment; Chronic drug treatment; Ethology; Resident intruder; Social hierarchy

Indexed keywords

1 AMINOCYCLOPROPANECARBOXYLIC ACID; 5 HYDROXYTRYPTOPHAN; AMISULPRIDE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; APOMORPHINE; BUPRENORPHINE; BUSPIRONE; CHLORDIAZEPOXIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; CLONIDINE; CLORGYLINE; FLUOXETINE; IMIPRAMINE; ISONIAZID; MAPROTILINE; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; MORPHINE; NORADRENALIN UPTAKE INHIBITOR; RESERPINE; SEROTONIN 1A AGONIST; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; TETRABENAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; YOHIMBINE;

ACUTE DRUG ADMINISTRATION; AGGRESSION; ANIMAL BEHAVIOR; ASSERTIVENESS; CHRONIC DRUG ADMINISTRATION; DEPRESSION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG RESPONSE; DRUG SENSITIVITY; EMOTION; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOCIAL BEHAVIOR; SOCIAL DOMINANCE; VALIDATION PROCESS;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; GREAT BRITAIN; HUMANS; REPRODUCIBILITY OF RESULTS;

EID: 11844288311     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053382250     Document Type: Review

References (289)

1. Jesberger JA, Richardson JS. Effects of antidepressant drugs on the behavior of olfactory bulbectomized and sham-operated rats. Behav Neurosci 1986; 100: 256-274.
2. Henn FA, McKinney WT. Animal models in psychiatry. In: Meltzer H Ed, Psychopharmacology: The Third Generation of Progress. New York, Raven 1987; 697-704.
3. McKinney WT. Animal models of depression: An overview. Psychiatr Dev 1984; 2: 77-96.
4. Willner P. The validity of animal models of depression. Psychopharmacology 1984; 83: 1-16.
5. Willner P. Animal models of depression: An overview. Pharmacol Ther 1990; 45: 425-455.
6. Danysz W, Archer T, Fowler CJ. Screening for new antidepressant compounds. In: Willner P Ed, Behavioural Models in Psychopharmacology: Theoretical, Industrial and Clinical Perspectives. Cambridge, Cambridge University Press 1991; 126-156.
7. Willner P. Behavioural models in psychopharmacology. In: Willner P Ed, Behavioural Models in Psychopharmacology: Theoretical, Industrial and Clinical Perspectives. Cambridge, Cambridge University Press 1991; 3-18.
8. Willner P, Mitchell PJ. Animal Models of Depression: A Diathesis/Stress Approach. In: D'haenen HAH, Den Boer JA, Willner P Eds, Biological Psychiatry. Chichester, Wiley 2002; 703-726.
9. Geyer MA, Markou A. Animal models of psychiatric disorders. In: Bloom F, Kupfer D Eds, Psychopharmacology: Fourth Generation of Progress. New York, Raven 1995; 787-798.
10. Weiss JM, Kilts. CD. Animal models of depression and schizophrenia. In: Schatzberg AF, Nemeroff CB Eds, Textbook of Psychopharmacology. Washington DC, American Psychiatric Press 1998; 89-131
11. Sarter M, Bruno JP. Animal models in Biological Psychiatry. In: D'haenen HAH, Den Boer JA, Willner P Eds, Biological Psychiatry. Chichester, Wiley 2002; 37-44.
12. Willner P. Depression: A psychobiological synthesis. A Wiley-Interscience publication. Chichester, John Wiley & Sons 1985; 597.
13. Emrich HM, Vogt P, Herz A. Possible antidepressant effects of opioids: Action of buprenorphine. Ann NY Acad Sci 1983; 398: 108-112.
14. Bodnoff SR, Suranyi-Cadotte B, Aitken DH, Quirion R, Meaney MJ. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology 1988; 95: 298-302.
15. Fontana DJ, Carbary TJ, Commisaris RL. Effects of acute and chronic anti-panic drug administration on conflict behavior in the rat. Psychopharmacology 1989; 98: 157-162.
16. Den Boer JA, Slaap BR, ter Horst GJ, Cremers TIFH, Bosker FJ. Therapeutic Armamentarium in Anxiety Disorders. In: D'haenen HAH, Den Boer JA, Willner P Eds, Biological Psychiatry. Chichester, Wiley 2002; 1039-1062.
17. Abramson LY, Seligman MEP. Modeling psychopathology in the laboratory: History and rationale. In: Maser JD, Seligman MEP Eds, Psychopathology: Experimental Models. San Francisco, Freeman 1978; 1-26.
18. Nelson JC, Charney DS. The symptoms of major depression. Am J Psychiatr 1981; 138: 1-13.
19. Willner P. Animal models as simulations of depression. Trends Pharmacol Sci 1991; 12: 131-136.
20. Frazer A, Lucki I, Sills M. Alterations in monoamine-containing neuronal function due to administration of antidepressants repeatedly to rats. Acta Pharmacol Toxicol 1985; 56(Suppl 1): 21-34.
21. Willner P. Sensitization to the actions of antidepressant drugs. In: Emmett-Oglesby MW, Goudie AJ Eds, Psychoactive Drugs: Tolerance and Sensitization. New Jersey, Humana Press 1989; 407-459.
22. Cuomo V, Cagiano R, Brunello N, Fumagalli R, Racagni G. Behavioural changes after acute and chronic administration of typical and atypical antidepressants in rat: Interactions with reserpine. Neurosci Lett 1983; 40: 315-319.
23. Niesink RJM, van Ree JM. Antidepressant drugs normalize the increased social behaviour of pairs of male rats induced by short term isolation. Neuropharmacology 1982; 21: 1343-1348.
24. Akiskal HS. Interaction of biologic and psychologic factors in the origin of depressive disorders. Acta Psychiatr Scand 1985; 71:131-139.
25. Akiskal HS. A developmental perspective on recurrent mood disorders: A review of studies in man. Psychopharmacol Bull 1986; 22:579-586.
26. Aneshensel CS, Stone JD. Stress and depression: A test of the buffering model of social support. Archives of Gen Psychiatry 1982; 39: 1392-1396.
27. Brown GW, Harris T. Social Origins of Depression. London, Tavistock 1978.
28. Lloyd C. Life events and depressive disorder reviewed. Arch Gen Psychiatry 1980; 37: 529-548.
29. Brown GW, Harris T, eds. Life Events and Illness. New York, Guilford Press 1988.
30. Weiss JM, Bailey WH, Goodman PA, Hoffman LJ, Ambrose MJ, Salman S, et al. A model for neurochemical study of depression. In: Spiegelstein MY, Levy A Eds, Behavioural Models and the Analysis of Drug Action. Amsterdam, Elsevier Scientific Publishing Company 1982; 195-223.
31. Brown GW. A psychosocial view of depression. In: Bennett D, Freeman H Eds, Community Psychiatry. London, Churchill-Livingstone 1989; 71-114.
32. Willner P. Towards a theory of serotonergic dysfunction in depression. In: Archer T, Bevan P, Cools A Eds, Behavioural Pharmacology of 5-HT. New York, Lawrence Erlbaum 1989; 157-178.
33. Seligman MEP. Helplessness: On Depression, Development and Death. San Francisco, Freeman 1975.
34. Glazer HI, Weiss JM. Long-term interference effect: an alternative to "learned helplessness". J Exp Psychol: Anim Behav Proc 1976; 2:201-213.
35. Anisman H, Irwin J, Sklar LS. Deficits of escape performance following catecholamine depletion: implications for behavioural deficits induced by uncontrollable stress. Psychopharmacology 1979; 64: 163-170.
36. Lewis JW, Cannon JT, Liebeskind JC. Opioid and non-opioid mechanisms of stress-induced analgesia. Science 1980; 208: 623-625.
37. Jackson RL, Maier SF, Rapoport PM. Exposure to inescapable shock produces both activity and associative deficits in rats. Learn Motiv 1978; 9: 69-98.
38. Minor TR, Jackson RL, Maier SF. Effects of task-irrelevant cues and reinforcement delay on choice-escape learning following inescapable shock: Evidence for a deficit in selective attention. J Exp Psychol: Anim Behav Proc 1984; 10: 543-556.
39. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 1987; 93: 358-364.
40. Willner P. Validity, reliability and utility of the chronic mild stress (CMS) model of depression: A ten-year review and evaluation. (Plus 17 peer commentaries and author's response). Psychopharmacology 1997; 134: 319-377.
41. Muscat R, Willner P. Suppression of sucrose drinking by chronic mild unpredictable stress: A methodological analysis. Neurosci Biobehav Rev 1992; 16: 519-524.
42. Matthews K, Forbes N, Reid IC. Sucrose consumption as a hedonic measure following chronic unpredictable mild stress. Physiol Behav 1995; 57: 241-248.
43. Moreau J-L, Jenck F, Martin JR, Mortas P, Haefely WE. Antidepressant treatment prevents chronic unpredictable mild stress- induced anhedonia as assessed by ventral tegmental self-stimulation behavior in rats. Eur Neuropsychopharmacol 1992; 2: 43-49.
44. Porsolt RD, Bertin A, Blavet N, Deniel M, Jalfre M. Immobility induced by forced swimming in rats: Effects of agents which modify central catecholamine and serotonin activity. European Journal of Pharmacology 1979; 57 201-210.
45. Fibiger HC. The dopamine hypotheses of schizophrenia and depression: Contradictions and speculations. In: Willner P, Scheel-Kruger J Eds, The Mesolimbic Dopamine System: From Motivation to Action. Chichester, John Wiley and Sons 1991; 615-637.
46. Kupfer DJ, Thase ME. The use of the sleep laboratory in the diagnosis of affective disorders. Psychiatr Clin North Am 1983; 6: 3-25.
47. Carroll BJ. The dexamethasone suppression test for melancholia. Br J Psychiatr 1982; 140: 292-304.
48. Van Praag HM. 5-HT-related anxiety- and/or aggression-driven depression. Int Clin Psychopharmacol 1994; 9(Suppl 1): 5-6.
49. Nelson JC. The use of antipsychotic drugs in the treatment of depression. In: Zohar J, Belmaker RH Eds, Treating Resistant Depression. New York, PMA Corp 1987; 131-146.
50. Lyon M. Animal models of mania and schizophrenia. In: Willner P Ed, Behavioural Models in Psychopharmacology: Theoretical, Industrial and Clinical Perspectives. Cambridge, Cambridge University Press 1991; 253-310.
51. Cairncross KD, Cox B, Forster C, Wren AF. Olfactory projection systems, drugs and behaviour: A review. Psychoneuroendocrinology 1979; 4: 253-272.
52. Mar A, Spreekmeester E, Rochford J. Antidepressants preferentially enhance habituation to novelty in the olfactory bulbectomized rat. Psychopharmacology (Berl) 2000; 150: 52-60.
53. Kelly JP, Wrynn AS, Leonard BE. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 1997; 74: 299-316.
54. Broekkamp CL, O'Connor WT, Tonnaer JADM, Rijk HW, Delft AMLV. Corticosterone, choline acetyltransferase and noradrenaline levels in olfactory bulbectomized rats in relation to changes in passive avoidance acquisition and open field activity. Physiol Behav 1986; 37: 429-434.
55. Borsini F, Cesana R, Kelly J, Leonard BE, McNamara M, Richards J, et al. BIMT 17: a putative antidepressant with a fast onset of action? Psychopharmacology (Berl) 1997; 134: 378-386.
56. McGrath C, Norman TR. (+)-S-20499 - a potential antidepressant? A behavioural and neurochemical investigation in the olfactory bulbectomised rat. Eur Neuropsychopharmacol 1999; 9: 21-27.
57. McGrath C, Norman TR. The effect of venlafaxine treatment on the behavioural and neurochemical changes in the olfactory bulbectomised rat. Psychopharmacology (Berl) 1998; 136: 394-401.
58. Harkin A, Kelly JP, McNamara M, Connor TJ, Dredge K, Redmond A, et al. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. Eur J Pharmacol 1999; 364: 123-132.
59. Van Riezen H, Leonard BE. Effects of psychotropic drugs on the behaviour and neurochemistry of olfactory bulbectomized rats. In: File SE Ed, Psychopharmacology of Anxiolytics and Antidepressants. New York, Pergamon 1990; 231-250.
60. Lloyd KG, Garrigou D, Broekkamp CLE. The action of monoaminergic, cholinergic and gabaergic compounds in the olfactory bulbectomized rat model of depression. In: Langer SZ, Takahashi R, Segawa T, Briley M Eds, New Vistas in Depression. New York, Pergamon Press 1982; 179-186.
61. Joly D, Sanger DJ. The effects of fluoxetine and zimelidine on the behavior of olfactory bulbectomized rats. Pharmacol Biochem Behav 1986; 24: 199-204.
62. Cryan JF, McGrath C, Leonard BE, Norman TR. Combining pindolol and paroxetine in an animal model of chronic antidepressant action - can early onset of action be detected? Eur J Pharmacol 1998; 352: 23-28.
63. Cryan JF, McGrath C, Leonard BE, Norman TR. Onset of the effects of the 5-HT1A antagonist, WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-DPAT-induced changes in the rat. Pharmacol Biochem Behav 1999; 63: 333-338.
64. Broekkamp CL, Garrigou D, Lloyd KG. Serotonin-mimetic and antidepressant drugs on passive avoidance learning by olfactory bulbectomized rats. Pharmacol Biochem Behav 1980; 13: 643-646.
65. Lumia AR, Teicher MH, Salchli F, Ayers E, Possidente B. Olfactory bulbectomy as a model for agitated hyposerotonergic depression. Brain Res 1992; 587: 181-185.
66. Leonard B. The olfactory bulbectomized rat as a model of depression. Eur Neuropsychopharmacol 1991; 1: 297-298.
67. Pepin MC, Pothier F, Barden N. Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature 1992; 355: 725-728.
68. Montkowski A, Barden N, Wotjak C, Stec I, Ganster J, Meaney M, et al. Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. J Neuroendocrin 1995; 7: 841-845.
69. Pepin MC, Pothier F, Barden N. Antidepressant drug action in a transgenic mouse model of endocrine changes seen in depression. Mol Pharmacol 1992; 42: 991-995.
70. Barden N. Modulation of glucocorticoid receptor gene expression by antidepressant drugs. Pharmacopsychiatry 1996; 29: 12-22.
71. Barden N. Regulation of corticosteroid receptor gene expression in depression and antidepressant action. J Psychiatry Neurosci 1999; 24: 25-39.
72. Farisse J, Boulenguez P, Semont A, Hery F, Barden N, Faudon M, et al. Regional serotonin metabolism under basal and restraint stress conditions in the brain of transgenic mice with impaired glucocorticoid receptor function. Neuroendocrinology 1999; 70: 413-421.
73. Linthorst AC, Flachskamm C, Barden N, Holsboer F, Reul JM. Glucocorticoid receptor impairment alters CNS responses to a psychological stressor: an in vivo microdialysis study in transgenic mice. Eur J Neurosci 2000; 12: 283-291.
74. Beaulieu S, Rousse I, Gratton A, Barden N, Rochford J. Behavioural charactyerization of a transgenic mouse model of impaired type II glucocorticoid receptor function. Soc Neurosci Abstr 1993; 19: 488-489.
75. Overstreet DH, Janowsky DS. A cholinergic supersensitivity model of depression. In: Boulton A, Baker G, Martin-Iverson M Eds, Neuromethods, Vol 20: Animal Models in Psychiatry. Basel, Birkhauser, 1991; 81-114.
76. Overstreet DH. The Flinders sensitive line rats: A genetic animal model of depression. Neurosci Biobehav Rev 1993; 17: 51-68.
77. Schiller GD, Pucilowski O, Wienicke C, Overstreet DH. Immobility-reducing effects of antidepressants in a genetic animal model of depression. Brain Res Bull 1992; 28: 821-823.
78. Overstreet DH. A behavioral, psychopharmacological and neurochemical update on the Flinders Sensitive Line rat, a potential genetic animal model of depression. Behav Genet 1991; 21: 67-74.
79. Overstreet DH, Pucilowski O, Rezvani AH, Janowsky DS. Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. Psychopharmacology (Berl) 1995; 121: 27-37.
80. Pucilowski O, Danysz W, Overstreet DH, Rezvani AH, Eichelman B, Janowsky DS. Decreased hyperthermic effect of MK-801 in selectively bred hypercholinergic rats. Brain Res Bull 1991; 26: 621-625.
81. Pucilowski O, Overstreet DH, Rezvani AH, Janowsky DS. Chronic mild stress-induced anhedonia: greater effect in a genetic rat model of depression. Physiol Behav 1993; 54: 1215-1220.
82. Zangen A, Overstreet DH, Yadid G. High serotonin and 5-hydroxyindoleacetic acid levels in limbic brain regions in a rat model of depression: normalization by chronic antidepressant treatment. J Neurochem 1997; 69: 2477-2483.
83. Zangen A, Overstreet DH, Yadid G. Increased catecholamine levels in specific brain regions of a rat model of depression: normalization by chronic antidepressant treatment. Brain Res 1999; 824:243-250.
84. Owens MJ, Overstreet DH, Knight DL, Rezvani AH, Ritchie JC, Bissette G, et al. Alterations in the hypothalamic-pituitary-adrenal axis in a proposed animal model of depression with genetic muscarinic supersensitivity. Neuropsychopharmacology 1991; 4: 87-93.
85. Tizabi Y, Overstreet DH, Rezvanil AH, Louis VA, Clark EJ, Jonowsky DS, et al. Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology (Berl) 1999; 142: 193-199.
86. Tizabi Y, Rezvanil AH, Russell LT, Tyler KY, Overstreet DH. Depressive characteristics of FSL rats: involvement of central nicotinic receptors. Pharmacol Biochem Behav 2000; 66: 73-77.
87. Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1991; 43: 425-473.
88. Aulakh CS, Hill JL, Murphy DL. Attenuation of hypercortisolemia in fawn-hooded rats by antidepressant drugs. European Journal of Pharmacology 1993; 240: 85-88.
89. Gomez F, Grauges P, Lopez-Calderon A, Armario A. Abnormalities of hypothalamic-pituitary-adrenal and hypothalamic-somatotrophic axes in Fawn-Hooded rats. Eur J Endocrinol 1999; 141: 290-296.
90. Lahmame A, Gomez F, Armario A. Fawn-hooded rats show enhanced active behaviour in the forced swimming test, with no evidence for pituitary-adrenal axis hyperactivity. Psychopharmacology (Berl) 1996; 125: 74-78.
91. Hall FS, Huang S, Fong GF, Pert A. The effects of social isolation on the forced swim test in Fawn hooded and Wistar rats. J Neurosci Methods 1998; 79: 47-51.
92. Overstreet DH, Rezvani A, Janowsky DS. Genetic animal models of depression and ethanol preference provide support for cholinetrgic and serotonergic involvement in depression and alcoholism. Biol Psychiatry 1992; 31: 919-936.
93. Hall FS, Huang S, Fong GW, Pert A, Linnoila M. Effects of isolation-rearing on voluntary consumption of ethanol, sucrose and saccharin solutions in Fawn Hooded and Wistar rats. Psychopharmacology (Berl) 1998; 139: 210-216.
94. Hall FS, Huang S, Fong GW, Sundstrom JM, Pert A. Differential basis of strain and rearing effects on open-field behaviour in Fawn Hooded and Wistar rats. Physiol Behav 2000; 71: 525-532.
95. 1A receptors in Fawn-Hooded rats after chronic fluoxetine treatment. Eur Neuropsychopharmacol 2001; 11: 15-24.
96. Kantor S, Anheuer ZE, Bagdy G. High social anxiety and low aggression in Fawn-Hooded rats. Physiol Behav 2000; 71: 551-557.
97. Aulakh CS, Tolliver T, Wozniak KM, Hill JL, Murphy DL. Functional and biochemical evidence for altered serotonergic function in the fawn-hooded rat strain. Pharmacol Biochem Behav 1994; 49: 615-620.
98. Aulakh CS, Mazzola-Pomietto P, Murphy DL. Long-term antidepressant treatment restores clonidine's effect on growth hormone secretion in a genetic animal model of depression. Pharmacol Biochem Behav 1996; 55: 265-268.
99. Jackson RL, Minor TR. Effects of signaling inescapable shock on subsequent escape learning: Implications for theories of coping and "learned helplessness". J Exp Psychol: Anim Behav Proc 1988; 14: 390-400.
100. Abramson LY, Seligman MEP, Teasdale JD. Learned helplessness in humans: Critique and reformulation. Journal of Abnormal Psychology 1978; 87: 49-74.
101. Abramson LY, Metalsky G, Alloy LB. Hopelessness depression: A theory-based subtype of depression. Psychological Reviews 1989; 96: 358-372.
102. Minor TR, Pelleymounter MA, Maier SF. Uncontrollable shock, forebrain norepinephrine, and stimulus selection during choice-escape learning. Psychobiology 1988; 16: 135-145.
103. Willner P. Validating criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10: 677-690.
104. Sherman AD, Sacquitne JL, Petty F. Specificity of the learned helplessnes model of depression. Pharmacol Biochem Behav 1982; 16: 449-454.
105. Martin P, Laporte AM, Soubrie P, El Mestikawy S, Hamon S. Reversal of helpless behaviour by serotonin reuptake inhibitors. In: Bevan P, Cools AR, T TA Eds, Behavioural Pharmacology of 5HT. New York, Erlbaum 1989; 231-234.
106. 1A agonists. Biological Psychiatry 1988; 23: 237-242.
107. Martin P, Soubrie P, Simon P. Shuttle-box deficits induced by inescapable shock in rats: reversal by the beta-adrenoreceptor stimulants clenbuterol and salbutamol. Pharmacol Biochem Behav 1986; 24: 177-181.
108. Christensen AV, Geoffroy M. The effect of different serotonergic drugs in the learned helplessness model of depression. In: Olivier B, Mos J, Slangen J Eds, Animal Models in Psychopharmacology. Basel, Birkhauser 1991; 205-209.
109. Gambarana C, Ghiglieri O, Tolu P, Montis MGD, Giachetti D, Bombardelli E, et al. Efficacy of an Hypericum perforatum (St. John's wort) extract in preventing and reverting a condition of escape deficit in rats. Neuropsychopharmacology 1999; 21: 247-257.
110. Kumar V, Singh PN, Bhattacharya SK. Anti-stress activity of Indian Hypericum perforatum L. Indian J Exp Biol 2001; 39: 344-349.
111. Teixeira NA, Pereira DG, Hermini AH. Chronic but not acute Li+ treatment prevents behavioral depression in rats. Braz J Med Biol Res 1995; 28: 1003-1007.
112. Brown L, Rosellini RA, Samuels OB, Riley EP. Evidence for a serotonergic mechanism of the learned helplessness phenomenon. Pharmacol Biochem Behav 1982; 17: 877-883.
113. Edwards E, Johnson J, Anderson D, Turano P, Henn FA. Neurochemical and behavioral consequences of mild uncontrollable shock: effects of PCPA. Pharmacol Biochem Behav 1986; 25: 415-421.
114. Cavoy A, Ennaceur A, Delacour J. Effects of piracetam on learned helplessness in rats. Physiol Behav 1988; 42: 545-549.
115. Porsolt RD, Lenegre A, McArthur RA. Pharmacological models of depression. In: Olivier B, Mos J, Slangen JL Eds, Animal Models in Psychopharmacology. Basel, Birkhauser 1991; 137-159.
116. Maier SF. Exposure to the stressor environment prevents the temporal dissipation of behavioral depression/learned helplessness. Biol Psychiatry 2001; 49: 763-773.
117. Desan PH, Silbert LH, Maier SF. Long-term effects of inescapable stress on daily running activity and antagonism by desipramine. Pharmacol Biochem Behav 1988; 30: 21-29.
118. Woodmansee WW, Silbert LH, Maier SF. Stress-induced changes in daily activity in the rat are modulated by different factors than are stress-induced escape-learning deficits. Soc Neurosci Abstr 1991; 17: 146
119. Zacharko RM, Bowers WJ, Kokkinidis L, Anisman H. Region-specific reductions of intracranial self-stimulation after uncontrollable stress: Possible effects on reward processes. Behav Brain Res 1983; 9: 129-141.
120. Zacharko RM, Lalonde GT, Kasian M, Anisman H. Strain specific effects of inescapable shock on intracranial self-stimulation from the nucleus accumbens. Brain Res 1987; 426: 164-168.
121. Zacharko RM, Anisman H. Stressor-provoked alterations of intracranial self-stimulation in the mesocortiolimbic dopamine system: an animal model of depression. In: Willner P, Scheel-Kruger J Eds, The Mesolimbic Dopamine System, From Motivation to Action. Chichester, Wiley 1991; 411-442.
122. Anisman HA, Zacharko RM. Depression: The predisposing influence of stress. Behav Brain Sci 1982; 5: 89-137.
123. Shanks N, Anisman H. Stressor-provoked behavioral changes in six strains of mice. Behav Neurosci 1988; 102: 894-905.
124. Vollmayr B, Henn FA. Learned helplessness in the rat: improvements in validity and reliability. Brain Res Brain Res Protoc 2001; 8: 1-7.
125. Shumake J, Poremba A, Edwards E, Gonzalez-Lima F. Congenital helpless rats as a genetic model for cortex metabolism in depression. NeuroReport 2000; 11: 3793-3798.
126. Drevets WC, Raichle ME. Reciprocal suppression of regional cerebral blood flow during emotional versus higher cognitive processes: Implications for interactions between emotion and cognition. Cognition and Emotion 1998; 12: 353-385.
127. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurian R, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness. Am J Psychiatr 1999; 156: 675-682.
128. King JA, Abend S, Edwards E. Genetic predisposition and the development of posttraumatic stress disorder in an animal model. Biol Psychiatr 2001; 50: 231-237.
129. Maier SF. Learned helplessness and animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 1984; 8: 435-446.
130. Besson A, Privat AM, Eschalier A, Fialip J. Effects of morphine, naloxone and their interaction in the learned-helplessness paradigm in rats. Psychopharmacology (Berl) 1996; 123: 71-78.
131. Besson A, Privat AM, Eschalier A, Fialip J. Reversal of learned helplessness by morphine in rats: involvement of a dopamine mediation. Pharmacol Biochem Behav 1998; 60: 519-525.
132. Besson A, Privat AM, Eschalier A, Fialip J. Dopaminergic and opioidergic mediations of tricyclic antidepressants in the learned helplessness paradigm. Pharmacol Biochem Behav 1999; 64: 541-548.
133. Gambarana C, Ghiglieri O, Tagliamonte A, D'Alessandro N, Montis MGD. Crucial role a D1 dopamine receptors in meditating the antidepressant effect of imipramine. Pharmacol Biochem Behav 1995; 50: 147-151.
134. Gambarana C, Ghiglieri O, Montis MGD. Desensitization of the D1 dopamine receptors in rats reproduces a model of escape deficit reverted by imipramine, fluoxetine and clomipramine. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 741-755.
135. De Montis MG, Gambarana C, Meloni D. Alpha-methyl-paratyrosine antagonizes the effect of chronic imipramine on learned helplessness in rats. Eur J Pharmacol 1993; 249: 179-183.
136. Martin P, Soubrie P, Simon P. Noradrenergic and opiod mediation of tricyclic-induced reversal of escape deficits caused by inescapable shock pretreatment in rats. Psychopharmacology 1986; 90: 90-94.
137. Meloni D, Gambarana C, De Montis MG, Dal Pra P, Taddei I, Tagliamonte A. Dizoclipine antagonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacol Biochem Behav 1993; 46: 423-426.
138. Nakagawa Y, Ishima T, Ishibashi Y, Tsuji M, Takashima T. Involvement of GABAB receptor systems in experimental depression: baclofen but not bicuculline exacerbatyes helplessness in rats. Brain Res 1996; 741: 240-245.
139. Nakagawa Y, Ishima T, Ishibashi Y, Tsuji M, Takashima T. Involvement of GABAB receptor systems in action of antidepressants. II: Baclofen attenuates the effect of desipramine whereas muscimol has no effect in learned helplessness paradigm in rats. Brain Res 1996; 728: 225-230.
140. Soubrie P, Martin P, El Mestikawy S, Thiebot MH, Simon P, Hamon M. The lesion of serotonergic neurons does not prevent antidepressant-induced reversal of escape failures produced by inescapable shocks in rats. Pharmacol Biochem Behav 1986: 25: 1-6.
141. Papolos DF, Yu YM, Rosenbaum E, Lachman HM. Modulation of learned helplessness by 5-hydroxytryptamine2A receptor antisense oligodeoxynucleotides. Psychiatry Res 1996; 63: 197-203.
142. 1A agonists and conventional antidepressants in an animal model of depression. European Journal of Pharmacology 1987; 134: 265-274.
143. Katz RJ, Roth KA, Carroll BJ. Acute and chronic stress effects on open field activity in the rat: implications for a model of depression. Neurosci Biobehav Rev 1981; 5: 247-251.
144. Soblosky JS, Thurmond JB. Biochemical and behavioral correlates of chronic stress: Effects of tricyclic antidepressants. Pharmacol Biochem Behav 1986; 24: 1361-1368.
145. Katz RJ. Animal model of depression: Pharmacological sensitivity of a hedonic deficit. Pharmacol Biochem Behav 1982; 16: 965-968.
146. Willner P, Sampson D, Papp M, Phillips G, Muscat R. Animal models of anhedonia. In: Soubrie P Ed, Animal Models of Psychiatric Disorders Vol 3, Anxiety, Depression and Mania. Basel, Karger 1991; 71-99.
147. Papp M, Willner P, Muscat R. An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology 1991; 104: 255-259.
148. Papp M, Lappas S, Muscat R, Willner P. Attenuation of place preference conditioning but not place aversion conditioning by chronic mild stress. J Psychopharmacol 1992; 6: 352-356.
149. Papp M, Muscat R, Willner P. Subsensitivity of rewarding and locomotor stimulant effects of a dopamine agonist following chronic mild stress. Psychopharmacol (Berl) 1993; 110: 152-158.
150. Willner P, Papp M. Animal models to detect antidepressants: Are new strategies necessary to detect new agents? In: Skolnick P Ed, Antidepressants: New Pharmacological Strategies. Totowa New Jersey, Humana 1997; 213-234.
151. Muscat R, Papp M, Willner P. Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacol (Berl) 1992; 109: 433-438.
152. Cheeta S, Broekkamp C, Willner P. Stereospecific reversal of stress-induced anhedonia by mianserin and its (+)-enantiomer. Psychopharmacology 1994; 116:523-528.
153. Monroe SM, Thase ME, Hersen M, Himmelhochh LM, Bellack AS. Life events and the endogenous-nonendogenous distinction in the treatment and posttreatment course of depression. Compr Psychiatr 1985; 26: 175-186.
154. Rodgers B. Models of stress, vulnerability and affective disorder. J Affect Disord 1991; 21: 1-13.
155. Papp M, Wieronska J. Antidepressant-like activity of amisulpride in two animal models of depression. J Psychopharmacol 2000; 14: 46-52.
156. Papp M, Moryl E. Antidepressant-like effects of I-aminocyclopropanecarboxylic acid and d-cycloserine in an animal model of depression. Eur J Pharmacol 1996; 316: 145-151.
157. D'Aquila P, Monleon S, Borsini F, Brain P, Willner P. Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant. European Journal of Pharmacology 1997; 340: 121-132.
158. Hyttel J, Bogeso KP, Perregaard J, Sanchez C. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 1992; 88(2): 157-160.
159. Sanchez C, Gruca P, Papp M. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 2003; 14: 465-470.
160. Sluzewska A, Szczawinska K. Lithium potentiation of antidepressants in chronic mild stress model of depression in rats. Behav Pharmacol 1996; 7(Suppl 1): 105.
161. Sluzewska A, Szczawinska K. The effects of pindolol addition to fluvoxamine and buspirone in chronic mild stress model of depression. Behav Pharmacol 1996; 7(Suppl 1): 105.
162. Dziedzicka-Wasylewska M, Willner P, Papp M. Changes in dopamine receptor mRNA expression following chronic mild stress and chronic antidepressant treatment. Behavioural Pharmacology 1997; 8: 607-618.
163. De Montis MG, Gambarana C, Ghiglieri O, Tagliamonte A. Reversal of stable behavioural modifications through NMDA receptor inhibition in rats. Behav Pharmacol 1995; 6: 562-567.
164. Ghiglieri O, Gambarana C, Scheggi S, Tagliamonte A, Willner P, Montis MGD. Palatable food induces an appetitive behaviour in satiated rats which can be inhibited by chronic stress. Behavioural Pharmacology 1997; 8: 619-628.
165. Gambarana C, Masi F, Tagliamonte A, Scheggi S, Ghiglieri O, Montis MGD. A chronic stress that impairs reactivity in rats also decreases dopaminergic transmission in the nucleus accumbens: A microdialysis study, J Neurochem 1999; 72: 2039-2046.
166. Leith NJ, Barrett RJ. Amphetamine and the reward system: evidence for tolerance and post-drug depression. Psychopharmacology 1976; 46: 19-25.
167. Simpson DM, Annau Z. Behavioural withdrawal following several psychoactive drugs. Pharmacol Biochem Behav 1977; 7: 59-64.
168. Barrett RJ, White DK. Reward system depression following chronic amphetamine: antagonism by haloperidol. Pharmacol Biochem Behav 1980; 13: 555-559.
169. Kokkinidis L, Zacharko RM. Response sensitization and depression following long-term amphatamine treatment in a self-stimulation paradigm. Psychopharmacology 1980; 68: 73-76.
170. Cassens GP, Actor C, Kling M, Schildkraut JJ. Amphetamine withdrawal effects threshold of intracranial self-stimulation. Psychopharmacology 1981; 73: 318-322.
171. Leith NJ, Barrett RJ. Effects of chronic amphetamine or reserpine on self-stimulation: Animal model of depression? Psychopharmacology 1980; 72: 9-15.
172. Kokkinidis L, Zacharko RM, Predy PA. Post-amphetamine depression of self-stimulation responding from the substantia nigra: reversal by tricyclic antidepressants. Pharmacol Biochem Behav 1980; 13: 379-383.
173. Koob GF. Anhedonia as an animal model of depression. In: Koob GF, Ehlers CL, Kupfer DJ Eds, Animal Models of Depression. Boston, Birkhauser 1989; 162-183.
174. Kornetsky C, Esposito RU. Reward and detection thresholds for brain stiulation: Dissociative effects of cocaine. Brain Res 1981; 209: 496-500.
175. Markou A, Hanley SJ, Chehade AK, Koob GF. Effects of performance and reward manipulations on current- intensity thresholds and other measures derived from a discrete-trial self-stimulation procedure in rats. Soc Neurosci Abstr 1989; 15: 35.
176. Markou A, Koob GF. Bromocriptine reverses post-cocaine anhedonia in a rat model of cocaine withdrawal. American College of Neuropsychopharmacology 1989; Abstracts: 157.
177. Markou A, Hauger RL, Koob GF. Desmethylimipramine attenuates cocaine withdrawal in rats. Psychopharmacology (Berl) 1992; 109: 305-314.
178. Post MD. Cocaine psychoses: A continuum model. Am J Psychiatr 1975; 132: 225-231.
179. Antelman SM, Eichler AJ, Black CA, Kocan D. Interchangeability of stress and amphetamine sensitization. Science 1980; 207: 329-331.
180. Sarnyai Z, Biro E, Gardi J, Vecsernyes M, Julesz J, Telegdy G. Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Res 1995; 675: 89-97.
181. Blanc G, Herve D, Simon H, Lisoprawski A, Glowinski J, Tassin JP. Response to stress of mesocortical frontal doparminergic neurons in rats after long-term isolation. Nature 1980; 284: 265-276.
182. Watson R, Hartman E, Schildkraut JJ. Amphetamine withdrawal: affective state, sleep patterns and MHPG excretion. Am J Psychiatr 1972; 129: 263-269.
183. Hoebel BG. Brain-stimulation reward and aversion in relation to behaviour. In: Wauquier A, Rolls E Eds, Brain-Stimulation Reward. New York, North Holland/ American Elsevier 1976; 331-372.
184. Gibson WE, Reid LD, Sakai M, Porter PB. Intracranial reinforcement compared with sugar-water reinforcement. Science 1965; 148: 1357-1358.
185. Valenstein ES. Brain Control: A Critical Examination of Brain Stimulation and Psychosurgery. New York, Wiley 1973.
186. Atrens DM. Self-stimulation and psychotropic drugs: A methodological and conceptual critique. In: Bond N Ed, Animal Models in Psychopathology. Sydney, Academic 1984; 227-256.
187. Wise RA. The brain and reward. In: Liebmann JM, Cooper SJ Eds, The Neuropharmacological Basis of Reward. Oxford, Oxford University Press 1989; 377-424.
188. Price JS. Genetic and phylogenetic aspects of mood variation. Int J Ment Health 1972; 1: 124-144.
189. Gardner R. Mechanisms in manic-depressive disorder: An evolutionary model. Arch Gen Psychiatry 1982; 39: 1436-1441.
190. Henry JP. The relation of social to biological processes in disease. Social Science Medicine 1982; 16: 369-380.
191. Toates F. Stress: Conceptual and Biological Aspects. Chichester, Wiley 1995.
192. Gilbert P, Allan S. The role of defeat and entrapment (arrested flight) in depression: an exploration of an evolutionary view. Psychological Medicine 1998; 28: 585-598.
193. Hersen M, Bellack AS, Himmelhoch JM, Thase ME. Effect of social skill training, amitriptyline and psychotherapy in unipolar depressed women. Behaviour Therapy 1984; 15: 21-40.
194. Everitt BJ, Keverne EB. Models of depression based on behavioural observations of experiemental animals. In: Paykel ES, Coppen A Eds, Psychopharmacology of Affective Disorders. Oxford, Oxford University Press 1979; 41-59.
195. Suomi SJ. Factors affecting responses to social separation in rhesus monkeys. In: Serban G, Kling A Eds, Animal Models in Human Psychobiology. New York, Plenum Press 1976; 9-26.
196. Robertson J, Bowlby J. Responses of young children to separation from their mothers. Cour du Centre Internationale de L'Enfance 1952; 2: 131-142.
197. Brown GW, Sklair F, Harris TO, Birley JLT. Life events and psychiatric disorders. I. Some methodological issues. Psychol Med 1973; 3: 74-87.
198. Schmale AH. Adaptive role of depression in health and disease. In: Scott JP, Senay E Eds, Separation and Depression. Washington, Amer Assoc Adv Sci 1973; 187-214.
199. Reite M, Short R, Seiler C, Pauley JD. Attachment, loss and depression. J Child Psychol Psychiat 1981; 22: 141-169.
200. Lewis JK, McKinney WT, Young LD, Kraemer GW. Mother-infant separation in rhesus monkeys as a model of human depression: A reconsideration. Arch Gen Psychiatry 1976; 33: 699-705.
201. Hrdina PD, Kulmiz PV, Stretch R. Pharmacological modification of experimental depression in infant macaques. Psychopharmacology 1979; 64: 89-93.
202. Suomi SJ, Seaman SF, Lewis JK, DeLizio RB, McKinney WT. Effects of imipramine treatment on separation- induced social disorders in rhesus monkeys. Arch Gen Psychiatry 1978; 35: 321-325.
203. McKinney WT, Kraemer GW. Effects of oxaprotiline on the response to peer separation in rhesus monkeys. Biol Psychiatr 1989; 25: 818-821.
204. Lewis JK, McKinney WT. Effects of electroconvulsive shock on the behaviour of normal and abnormal rhesus monkeys. Behav Psychiatr 1976; 37: 687-693.
205. Menzel EW, Davenport RK, Rogers CM. Effects of environmental restriction upon the chimpanzee's responsiveness to objects. J Comp Physiol Psychol 1963; 56: 78-85.
206. Turner C, Davenport R, Rogers C. The effect of early deprivation on the social behaviour of adolescent chimpanzees. Am J Psychiatr 1969; 125: 1531-1536.
207. McKinney WT, Young LD, Suomi SJ. Chlorpromazine treatment of disturbed monkeys. Arch Gen Psychiatry 1973; 29: 490-494.
208. Kraemer GW, Ebert MH, Schmidt DE, McKinney WT. A longitudinal study of the effect of different rearing conditions on cerebrospinal fluid norepinephrine and biogenic amine metabolism in rhesus monkeys. Neuropsychopharmacology 1989; 2: 175-189.
209. Kraemer GW, Ebert MH, Lake CR, McKinney WT. Hypersensitivity to d-amphetamine several years after early social deprivation in Rhesus monkeys. Psychopharmacology 1984; 82: 266-271.
210. Kraemer GW, Ebert MH, Lake CR, McKinney WT. Cerebrospinal fluid measures of neurotransmitter changes associated in the pharmacological alteration of the despair response to social separation in rhesus monkeys. Psychiatr Res 1984; 11: 303-315.
211. McKinney WT, Bunney WE. Animal model of depression: Review of evidence and implications for research. Arch Gen Psychiatry 1969; 21: 240-248.
212. Katz RJ. Animal models and human depressive disorders. Neurosci Biobehav Rev 1981; 5: 231-246.
213. Lehr E. Distress-call reactivation in isolated chicks: A behavioural indicator with high selectivity for antidepressants. Psychopharmacology 1989; 97: 145-146.
214. Rupniak NM, Carlson EC, Harrison T, Oates B, Seward E, Owens S, et al. Pharmacological blockade or genetic deletion of substance P(NK1) receptors attenuates neonatal vocalization in guinea-pigs and mice. Neuropharmacology 2000; 39: 1413-1421.
215. Berger BD, Schuster R. An animal model of social interaction: Implications for the analysis of drug action. In: Spiegelstein M, Levy A Eds, Behavioral Models and the Analysis of Drug Action. Amsterdam, Elsevier 1982; 415-428.
216. Lewinsohn PM. A behavioural approach to depression. In: Friedman RJ, Katz MM Eds, The Psychology of Depression: Contemporary Theory and Research. New York, Winston/Wiley 1974; 157-185.
217. Willner P, Sampson D, Phillips G, Fichera R, Foxlow P, Muscat R. Effects of isolated housing and chronic antidepressant treatment on cooperative social behaviour in rats. Behav Pharmacol 1989; 1: 85-90.
218. Albonetti ME, Farabollini F. Social stress by repeated defeat: effects on social behaviour and emotionality. Behav Brain Res 1994; 62: 187-193.
219. Koolhaas JM, Hermann PM, Kemperman C, Bohus B, Van der Hoofdakker RH, Beersma DG. Single social defeat in male rats induces a gradual but long lasting behavioral change: A model of depression? Neurosci Res Com 1990; 7: 35-41.
220. Korte SM, Smit J, Bouws GAH, Koolhaas JM, Bohus B. Neuroendocrine evidence for hypersensitivity in serotonergic neuronal system after psychosocial stress of defeat. In: Olivier B, Mos J, Slangen J Eds, Animal Models in Psychopharmacology. Basel, Birkhauser 1991; 199-203.
221. Kudryatseva NN, Bakshtanovskaya IV, Koryakina LA. Social model of depression in mice of C57BL/6J strain. Pharmacol Biochem Behav 1991; 38: 315-320.
222. Willner P, D'Aquila PS, Coventry T, Brain P. Loss of social status: preliminary evaluation of a novel animal model of depression. J Psychopharmacol 1995; 9: 207-213.
223. Coventry TL, D'Aquila PS, Brain P, Willner P. Social influences on morphine conditioned place preference. Behav Pharmacol 1997; 6-7(575-584):
224. Keeney AJ, Hogg S. Behavioural consequences of repeated social defeat in the mouse: preliminary evaluation of a potential animal model of depression. Behav Pharmacol 1999; 10: 753-764.
225. Keeney AJ, Hogg S, Marsden CA. Alterations in core body temperature, locomotor activity, and corticosterone following acute and repeated social defeat of male NMRI mice. Physiol Behav 2001; 74: 177-184.
226. Berton O, Durand M, Aguerre S, Mormede P, Chaouloff F. Behavioral, neuroendocrine and serotonergic consequences of single social defeat and repeated fluoxetine pretreatment in the Lewis rat strain. Neuroscience 1999; 92: 327-341.
227. Dixon AK, Fisch HU, Huber C, Walser A. Ethological studies in animals and man: Their use in psychiatry. Pharmacopsychiat 1989; 22(suppl. 1): 44-50.
228. Eisen A. Fluoxetine and desipramine: A strategy for augmenting anti-depressant response. Pharmacopsychiat 1989; 22: 272-273.
229. Khan A, Cohen S, Dager S, Avery DH, Dunner DL. Onset of response in relation to outcome in depressed outpatients with placebo and imipramine. J Affect Dis 1989; 17: 33-38.
230. Oswald I, Brezinova V, Dunleavy DLF. On the slowness of action of tricyclic antidepressant drugs. Br J Psychiatry 1972; 120: 673-677.
231. Priest RG, Beaumont G, Raptopoulos P. Suicide, attempted suicide and antidepressant drugs. Journal of International Medical Research 1980; 8(Suppl. 3): 8-13.
232. Kaplan SM, Kravetz RS, Ross WD. The effects of imipramine on the depressive components of medical disorders. In, Proc 3rd World Congress in Psychiatry 1961; 1362-1367.
233. Chance MRA, Silverman AP. The structure of social behaviour and drug action. In: Steinberg H, De Reuck AVS, Knight J Eds, CIBA-Symposium: Animal Behaviour and Drug Action. London, Churchill 1964; 65-79.
234. Grant EC. An analysis of the social behaviour of the male laboratory rat. Behaviour 1963; 21: 260-281.
235. Grant EC, Mackintosh JH. A comparison of the social postures of some common laboratory rodents. Behaviour 1963; 21: 246-259.
236. Grant EC, Chance MRA. Rank order in caged rats. Anim Behav 1958; 6: 183-194.
237. Silverman AP. Ethological and statistical analysis of drug effects on the social behaviour of laboratory rats. British Journal of Pharmacology 1965; 24: 579-590.
238. File SE, Hyde JRG. Can social interaction be used to measure anxiety? Br J Pharmacol 1978; 62: 19-24.
239. Bolles RC, Woods PJ. The ontogeny of behaviour in the albino rat. Anim Behav 1964; 12: 427-441.
240. Einon DF, Morgan MJ, Kibbler CC. Brief periods of socialization and later behavior in the rat. Dev Psychobiol 1978; 11: 213-225.
241. File SE, Pope JH. Social interaction between drugged and undrugged rats. Animal Learning and Behavior 1974; 2(3): 161-164.
242. Latane B. Gregariousness and fear in laboratory rats. J Exp Social Psychol 1969; 5: 61-69.
243. Barnett SA. The Rat. A study in behaviour. 2nd ed. Chicago and London, The University of Chicago Press 1975.
244. Gentsch C, Lichtsteiner M, Feer H. Competition for sucrose-pellets in triads of male Wistar rats: the individuals' performances are differing but stable. Behavioural Brain Research 1988; 27: 37-44.
245. Koolhaas JM, Schurmann T, Wiepkema PR. The organization of intraspecific agonistic behaviour in the rat. Progress in Neurobiology 1980; 15: 247-268.
246. Mitchell PJ. Ethological studies of the social behaviour of the rat. Animal Technology 1993; 44(2): 105-117.
247. Scott JP. Aggression. Chicago, The University of Chicago Press 1958.
248. Blanchard RJ, Fukunaga K, Blanchard DC, Kelly MJ. Conspecific aggression in the laboratory rat. J Comp Physiol Psychol 1975; 89(10): 1204-1209.
249. Raleigh MJ, Brammer GL, McGuire MT, Yuwiler A. Dominant social status facilitates the behavioural effects of serotonergic agonists. Brain Research 1985; 348: 274-282.
250. Mitchell PJ, Redfern PH. Acute and chronic antidepressant drug treatments induce opposite effects in the social behaviour of rats. Journal of Psychopharmacology 1992; 6(2): 241-257.
251. Mitchell PJ, Hogg S. Escitalopram: Behavioural model predicts antidepressant activity. World J Biol Psychiatry 2001; 2(Suppl1): Abstract P024-021.
252. Martin P. Effects of losartan, an angiotensin II antagonist, alone and in combination with antidepressant drugs (ADS) in an animal model of depression. FASEB J 1994; 8(4): A378 (2187).
253. B receptor antagonist, L-365, 260, elicits antidepressant-type effects in the forced-swim test in mice. Eur J Pharmacol 1994; 261: 257-263.
254. Mitchell PJ, Fairhall SJ, Fletcher A, Redfern PH. Effects of single and repeated electroconvulsive shock on the social and agonistic behaviour of resident rats. Neuropharmacology 2003; 44(7): 911-925.
255. Willner P, Theodorou A, Montomery A. Subchronic treatment with the tricyclic antidepressant DMI increases isolation-induced fighting in rats. Pharmacol Biochem Behav 1981; 14(4): 475-479.
256. Mitchell PJ, Forster EA. Gepirone exhibits antidepressant-like activity on the social/agonistic behaviour of resident rats. Journal of Psychopharmacology Abstract Book BAP/ESBP Meeting 1992: Abstract 335.
257. Mitchell PJ, Fletcher A. Venlafaxine exhibits pre-clinical antidepressant activity in the resident-intruder social interaction paradigm. Neuropharmacology 1993; 32(10): 1001-1009.
258. 1A ligands on the agonistic behaviour of rats. Journal of Psychopharmacology Abstract Book BAP/ISBP Meeting 1994; 8: Abstract 24.
259. 1A receptors. Journal of Psychopharmacology Abstract Book BAP/ISBP Meeting 1994; 8: Abstract 25.
260. Mitchell PJ, Fletcher A. Repeated electroconvulsive shock increases aggressive behaviour in resident rats. Soc Neurosci Abstr 1994; 20: 385 (Abst 164.312).
261. Mitchell PJ, Redfern PH. Effects of citalopram and paroxetine on rodent social and agonistic behaviour. Journal of Psychopharmacology 1997; 11(Suppl 3): Abstract 161.
262. Mitchell PJ, Redfern PH. Chronic treatment with d-amphetamine induces social withdrawal in resident rats. Journal of Psychopharmacology 1997; 11 (Suppl 3): Abstract 312.
263. Mitchell PJ, Redfern PH. Effects of m-chlorophenylpiperazine and mesulergine on rodent agonistic behaviour. J Psychopharmacacology 2000; 14(Suppl): A32(Abstr PD32).
264. Mitchell PJ, Hogg S. Escitalopram: Rapid antidepressant activity in rats. World J Biol Psychiatry 2001; 2(Suppl 1): Abstract P024-019.
265. File SE, Tucker JC. Behavioral consequences of antidepressant treatment in rodents. Neurosci Biobehav Rev 1986; 10: 123-134.
266. Fava M, Rosenbaum JF. Psychopharmacology of pathologic aggression. Harvard Rev Psychiatry 1993; 1: 244-246.
267. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behaviour in personality-disordered subjects. Arch Gen Psychiatry 1997; 54: 1081-1088.
268. Evenden J. Impulsivity: a discussion of clinical and experimental findings. J Psychopharmacol 1999; 13: 180-192.
269. Vartiainen H, Tiihonen J, Putkonen A, Koponen H, Virkkunen M, Hakola P, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatrica Scand 1995; 91: 348-351.
270. Hollander E. Managing aggressive behavior in patients with obsessive-compulsive disorder and borderline personality disorder. J Clin Psychiatry 1999; 60: S38-S44.
271. Lumley LA, Charles RF, Charles RC, Hebert MA, Morton DM, Meyerhoff JL. Effects of social defeat and of diazepam on behavior in a resident-intruder test in male DBA/2 mice. Pharmacol Biochem Behav 2000; 67: 433-447.
272. Gartside SE, Umbers V, Hajos M, Sharp T. Interaction between a selective 5-HT(1A) receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. British Journal of Pharmacology 1995; 115(6): 1064-1070.
273. Artigas F. 5-HT and antidepressants: new views from microdialysis studies. Trends in Pharmacological Sciences 1993; 14: 262.
274. Blier P, De Montigny C. Current advances and trends in the treatment of depression. Trends in Pharmacological Sciences 1994; 15: 220-226.
275. Mitchell PJ, Redfern PH. Potentiation of the time-dependent, antidepressant-induced changes in the agonistic behaviour of resident rats by the 5-HT1A receptor antagonist, WAY-100635. Behavioural Pharmacology 1997; 8: 585-606.
276. 2C receptor-mediated function. Soc Neurosci Abstr 2000; 26: 381-385.
277. File SE. Effects of chlordiazepoxide on competition for a preferred food in the rat. Behavioural Brain Research 1986; 21: 195-202.
278. Joly D, Sanger DJ. Social competition in rats: A test sensitive to acutely administered anxiolytics. Behavioural Pharmacology 1991; 2:205-213.
279. Joly D, Sanger DJ. Social competition in rats can be attenuated by anxiogenic drugs. Behavioural Pharmacology 1992; 3: 83-88.
280. Mitchell J, Lewis R, Wilson M. Effect of D-amphetamine on sexual competition in rats. Pharmacologist 1985; 27: 123.
281. Syme GJ, Pollard JS, Syme LA, Reid RM. An analysis of the limited access measure of social dominance in rats. Animal Behaviour 1974; 22: 486-500.
282. Benton D. Is the concept of dominance useful in understanding rodent behaviour? Aggressive Behav 1982; 8: 104-107.
283. Craig JV. Measuring social behaviour: Social dominance. J Animal Sci 1986; 62: 1120-1129.
284. Mitchell PJ, Redfern PH. Chronic treatment with clomipramine and mianserin increases the hierarchical position of subdominant rats housed in triads. Behavioural Pharmacology 1992; 3(3): 239-247.
285. Gentsch C, Lichtsteiner M, Feer H. Competition for sucrose-pellets in triads of male Wistar rats: effects of acute and subchronic chlordiazepoxide. Psychopharmacology 1990; 100: 530-534.
286. Moledina A, Mitchell PJ, Redfern PH. Effects of m-chlorophenylpiperazine on social competition in male Wistar rats. J Psychopharmacacology 2000; 14(Suppl): A39(PD28).
287. Lagget M, Rizzetto M. Treatment of chronic hepatitis B. Curr Pharm Design 2002; 8(11): 953-8.
288. Schechter LE, Dawson LA, Harder JA. The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease. Curr Pharm Design 2002; 8(2): 139-45.
289. Westra HA, Stewart SH. As-needed use of benzodiazepines in managing clinical anxiety: incidence and implications. Curr Pharm Design 2002; 8(1): 59-74.